Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteros biostructures has agreed to perform research to discover small molecule lead compounds against a specific target for delivery to Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), under an agreement signed between the companies.
Subscribe to our email newsletter
As per the agreement, Proteros is expected to deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Proteros CEO Torsten Neuefeind said that this partnership will build on a long standing and successful relationship.